Journal of Endocrinological Investigation

, Volume 32, Issue 10, pp 857–864 | Cite as

SIAMS-ONIG Consensus on hormonal treatment in gender identity disorders

  • A. Godano
  • M. Maggi
  • E. Jannini
  • M. C. Meriggiola
  • E. Ghigo
  • O. Todarello
  • A. Lenzi
  • C. Manieri


Cross sex treatment gender identity disorders (GID) real life experience (RLE) sex reassignment 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Osservatorio Nazionale sull’Identità di Genere — ONIG. Italian Standards of Care for Sex Reassignment in Gender Identity Disorder.
  2. 2.
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSMIVTR) (4th ed, Text Revision). Washington DC: American Psychiatric Association, 2000.Google Scholar
  3. 3.
    Zitzmann M. The role of the CAG repeat androgen receptor polymorphism in andrology. Front Horm Res 2009, 37: 52–61.PubMedCrossRefGoogle Scholar
  4. 4.
    Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E. X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients. J Clin Endocrinol Metab 2004, 89: 6208–17.PubMedCrossRefGoogle Scholar
  5. 5.
    Dahl M, Feldman JL, Goldberg JM, Jaberi A. Physical aspects of trans-gender endocrine therapy. Int J Transgenderism 2006, 9: 111–34.CrossRefGoogle Scholar
  6. 6.
    Asscheman H, Gooren LJ, Assies J, Smits JP, de Slegte R. Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals. Clin Endocrinol (Oxf) 1988, 28: 583–8.CrossRefGoogle Scholar
  7. 7.
    Istituto Superiore di Sanità. Conferenza Nazionale di Consenso. Salute della donna. Prevenzione delle complicanze trombotiche associate all’uso di estro-progestinici in età riproduttiva. Roma, 18–19 settembre 2008.Google Scholar
  8. 8.
    Benjamin H. Il fenomeno transessuale. Rome: Astrolabio Ubaldini Editore, 1966.Google Scholar
  9. 9.
    Futterweit W. Endocrine therapy of transsexualism and potential complications of long-term treatment. Arch Sex Behav 1998, 27: 209–26.PubMedCrossRefGoogle Scholar
  10. 10.
    Godano A. Terapia medica nel transessualismo. G Ital Androl 1995, 2: 160–4.Google Scholar
  11. 11.
    Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol (Oxf) 2003, 59: 409–18.CrossRefGoogle Scholar
  12. 12.
    Jannini EA, Lenzi A, Wagner G. Behavioural therapy and counselling. In: Schill WB, Comhaire FH, Hargreave TB eds. Andrology for the Clinician. Berlin: Springer. 2006. 598–607.CrossRefGoogle Scholar
  13. 13.
    Gooren LJ, Delemarre Van de Waal A. Hormone Treatment of Adult and Juvenile Transsexual Patients. In: Ettner R, Monstrey S, Eyler E eds. Principles of transgender medicine and surgery. The New York: Haworth Press, 2007.Google Scholar
  14. 14.
    Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 2008, 93: 19–25.PubMedCrossRefGoogle Scholar
  15. 15.
    Manieri C, Godano A, Lanfranco F, Di Bisceglie C, Ghigo E, Maggi M, Lenzi A, Jannini EA. Hormone treatment in gender dysphoria. Sexologies 2008, 17: 265–70.CrossRefGoogle Scholar
  16. 16.
    Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al; Endocrine Society. Endocrine treatment of transsexuals persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009, 94: 3132–54.PubMedCrossRefGoogle Scholar
  17. 17.
    Cohen-Kettenis PT, Delemarre-van de Waal HA, Gooren LJ. The treatment of adolescent transsexuals: changing insight. J Sex Med 2008, 5: 1892–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Dittrich R, Binder H, Cupisti S, Hoffmann I, Beckmann MW, Mueller A. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diab 2005, 113: 586–92.CrossRefGoogle Scholar
  19. 19.
    Mueller A, Kiesewetter F, Binder H, Beckmann MW, Dittrich R. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. J Clin Endocrinol Metab 2007, 92: 3470–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Jacobeit JW, Gooren LJ, Schulte HM. Long-acting intramuscular testosterone undecanoate for treatment of female-to-male trans-gender individuals. J Sex Med 2007, 4: 1479–84.PubMedCrossRefGoogle Scholar
  21. 21.
    Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexuals people: a review of treatment regimens, outcomes and adverse effects. J Clin Endocrinol Metab 2003, 88: 3467–73.PubMedCrossRefGoogle Scholar
  22. 22.
    Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2008, 159: 197–202.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2009

Authors and Affiliations

  • A. Godano
    • 1
  • M. Maggi
    • 2
  • E. Jannini
    • 3
  • M. C. Meriggiola
    • 4
  • E. Ghigo
    • 5
  • O. Todarello
    • 6
  • A. Lenzi
    • 7
  • C. Manieri
    • 5
  1. 1.ASL 1 Piedmont Region (ONIG Past President)TurinItaly
  2. 2.Andrology Unit, Department of Clinical PhysiopatologyUniversity of FlorenceFlorenceItaly
  3. 3.School of Sexology, Department of Experimental MedicineUniversity of L’AquilaL’AquilaItaly
  4. 4.Center for reproductive Health, Department of Obstetrics and GynecologyS. Orsola Hospital, University of BolognaBolognaItaly
  5. 5.Division of Endocrinology, Diabetology and Metabolism, Department of Internal MedicineUniversity of TurinTurinItaly
  6. 6.Department of Neurological and Psychiatric SciencesUniversity of Bari (ONIG President)BariItaly
  7. 7.Department of Medical PathophysiologyUniversity of RomeRome (SIAMS President)Italy

Personalised recommendations